QS Investors’s Celldex Therapeutics CLDX Stock Holding History

QS Investors’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-25,769	Closed	-$77K	–	1680
2018 Q4	$77K	Hold	25,769	–	–	﹤0.01%	1384
2018 Q3	$174K	Hold	25,769	–	–	﹤0.01%	1240
2018 Q2	$195K	Hold	25,769	–	–	﹤0.01%	1223
2018 Q1	$901K	Sell	25,769 -1,609	-6%	-$62.3K	0.01%	808
2017 Q4	$1.17M	Sell	27,378 -1,247	-4%	-$53.4K	0.01%	763
2017 Q3	$1.23M	Sell	28,625 -624	-2%	-$23.4K	0.01%	760
2017 Q2	$1.08M	Sell	29,249 -105	-0.4%	-$4.64K	0.01%	763
2017 Q1	$1.59M	Hold	29,354	–	–	0.01%	665
2016 Q4	$1.56M	Buy	29,354 +27,591	+1,565%	+$1.57M	0.01%	673
2016 Q3	$107K	Buy	+1,763	New	+$110K	﹤0.01%	1250
2016 Q1	–	Sell	-1	Closed	-$1K	–	1993
2015 Q4	$1K	Buy	+1	New	+$218	﹤0.01%	1583

Other funds holding CLDX

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

QS Investors's CLDX Position: Q1 2019 in Review

QS Investors sold out of Celldex Therapeutics (CLDX) in Q1 2019, closing a stake of 25,769 shares — an estimated $77K sold.

QS Investors first reported a position in CLDX in Q4 2015 and held it in 11 quarters. The position peaked at $1.59M in Q1 2017. 53 funds tracked by Wall St. Rank hold CLDX as of Q1 2019.

QS Investors reported no remaining Celldex Therapeutics position as of Q1 2019 after selling out during the quarter.
QS Investors sold 25,769 Celldex Therapeutics shares in Q1 2019, an estimated $77K.
QS Investors first reported a position in Celldex Therapeutics in Q4 2015 and held it in 11 quarters.
QS Investors's Celldex Therapeutics position peaked at $1.59M in Q1 2017.
53 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2019.

Based on QS Investors's 13F filing for Q1 2019, filed 15 May 2019.